HUMA

Humacyte Inc

HUMA, USA

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

https://humacyte.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
HUMA
stock
HUMA

Humacyte Stock (HUMA) Opinions on FDA Approval for Symvess Product Quiver Quantitative

Read more →
HUMA
stock
HUMA

Humacyte (HUMA): Benchmark remains bullish on stock MSN

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$7.8571

Analyst Picks

Strong Buy

5

Buy

1

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-43.71

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

368.55 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-19.13 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-3,181.01 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 41.80% of the total shares of Humacyte Inc

1.

BlackRock Inc

(6.2798%)

since

2025/06/30

2.

Vanguard Group Inc

(4.4197%)

since

2025/06/30

3.

State Street Corp

(2.7727%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(2.3844%)

since

2025/07/31

5.

CenterBook Partners LP

(2.1659%)

since

2025/06/30

6.

iShares Russell 2000 ETF

(1.8871%)

since

2025/08/31

7.

Geode Capital Management, LLC

(1.8618%)

since

2025/06/30

8.

Marshall Wace Asset Management Ltd

(1.6665%)

since

2025/06/30

9.

Millennium Management LLC

(1.612%)

since

2025/06/30

10.

UBS Group AG

(1.5441%)

since

2025/06/30

11.

SPDR® S&P Biotech ETF

(1.4252%)

since

2025/08/31

12.

Woodline Partners LP

(1.2637%)

since

2025/06/30

13.

Two Sigma Investments LLC

(0.9707%)

since

2025/06/30

14.

Susquehanna International Group, LLP

(0.8944%)

since

2025/06/30

15.

Morgan Stanley - Brokerage Accounts

(0.8692%)

since

2025/06/30

16.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8093%)

since

2025/07/31

17.

Fidelity Small Cap Index

(0.7936%)

since

2025/06/30

18.

Northern Trust Corp

(0.6583%)

since

2025/06/30

19.

Private Advisor Group, LLC

(0.6331%)

since

2025/06/30

20.

Charles Schwab Investment Management Inc

(0.5821%)

since

2025/06/30

21.

iShares Russell 2000 Value ETF

(0.5259%)

since

2025/08/31

22.

iShares Biotechnology ETF

(0.4689%)

since

2025/08/31

23.

LPL Financial Corp

(0.4577%)

since

2025/06/30

24.

MEDICAL BioHealth EUR Acc

(0.4536%)

since

2025/06/30

25.

GSA Capital Partners LLP

(0.4065%)

since

2025/06/30

26.

Goldman Sachs Group Inc

(0.4026%)

since

2025/06/30

27.

AQR Capital Management LLC

(0.4007%)

since

2025/06/30

28.

Citadel Advisors Llc

(0.3945%)

since

2025/06/30

29.

Fidelity Extended Market Index

(0.3929%)

since

2025/07/31

30.

Vanguard Russell 2000 ETF

(0.3786%)

since

2025/07/31

31.

Schwab US Small-Cap ETFâ„¢

(0.345%)

since

2025/08/30

32.

State St Russell Sm Cap® Indx SL Cl I

(0.2777%)

since

2025/08/31

33.

Vanguard Health Care ETF

(0.2403%)

since

2025/07/31

34.

Schwab Small Cap Index

(0.1988%)

since

2025/07/31

35.

NT R2000 Index Fund - NL

(0.1915%)

since

2025/06/30

36.

iShares Micro-Cap ETF

(0.1785%)

since

2025/08/31

37.

iShares Russell 2000 Growth ETF

(0.1701%)

since

2025/08/31

38.

NT R2000 Index Fund - DC - NL - 3

(0.1527%)

since

2025/06/30

39.

iShares Russell 2000 Small-Cap Idx Instl

(0.1371%)

since

2025/07/31

40.

Fidelity Total Market Index

(0.1333%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.1415

EPS Estimate

-0.1591

EPS Difference

0.0176

Surprise Percent

11.0622%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(6.8)
GARP
Fair GARP(4.5)
Growth
Moderate Growth(4.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(3)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.